Retraction: Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant

  • Anatoly Urisman,
  • Ross J Molinaro,
  • Nicole Fischer,
  • Sarah J Plummer,
  • Graham Casey,
  • Eric A Klein,
  • Krishnamurthy Malathi,
  • Cristina Magi-Galluzzi,
  • Raymond R Tubbs,
  • Don Ganem,
  • Robert H Silverman,
  • Joseph L DeRisi
  • Published: September 18, 2012
  • DOI: 10.1371/annotation/7e2efc01-2e9b-4e9b-aef0-87ab0e4e4732

In light of the findings from a recent study “In-Depth Investigation of Archival and Prospectively Collected Samples Reveals No Evidence for XMRV Infection in Prostate Cancer” (​.0044954)and others in the field, the editors of PLOS Pathogens have issued a retraction of this study. The association of XMRV with prostate cancer has now been thoroughly refuted. Although the original finding of a novel gammaretrovirus, XMRV, with the use of a pan-viral detection microarray is valid, and sequencing and phylogenetic characterization of the virus still stands, the editors agree that it is clear that XMRV found in this study is laboratory-derived and there is no association of XMRV with prostate cancer. As a result the paper was retracted from PLOS Pathogens on September 18th, 2012.